Andrew Dalovisio, MD
Hematology & Oncology · Baton Rouge, LANPI 1144458704
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $80,791 of the $127,853 with a category attached, or 63.2%. Johnson & Johnson accounts for 61.0% of it on its own, with 32 other manufacturers making up the rest. Among hematology & oncology clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 211 payments — averaging $605.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$78K
- AstraZeneca$28K
- Genmab U.S., Inc.$6K
- Janssen Scientific Affairs, LLC$5K
- Pfizer$3K
- Janssen Global Services, LLC$3K
- plus $5K from 27 others
Across 59 payments — averaging $4655.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$132K
- Pfizer$63K
- F. Hoffmann-la Roche AG$34K
- Agios Pharmaceuticals, Inc.$23K
- Genentech, Inc.$20K
- Novartis$2K
What the payments were for
- Consulting fees$38,26430%
- Speaking & faculty fees$80,79163%
- Travel & lodging$4,2903%
- Food & beverage$4,2983%
- Education$2100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 74 | $77,936 |
| AstraZeneca | 32 | $27,826 |
| Genmab U.S., Inc. | 10 | $6,051 |
| Janssen Scientific Affairs, LLC | 11 | $5,416 |
| Pfizer | 4 | $2,663 |
| Janssen Global Services, LLC | 1 | $2,503 |
| CTI Biopharma Corp. | 1 | $1,725 |
| Beigene USA, Inc. | 2 | $704 |
| Karyopharm Therapeutics Inc. | 5 | $703 |
| GSK | 6 | $533 |
| Novartis | 6 | $326 |
| Daiichi Sankyo Inc. | 8 | $256 |
| Adaptive Biotechnologies Corporation | 4 | $192 |
| AbbVie | 8 | $161 |
| Incyte Corporation | 1 | $99 |
| Bristol Myers Squibb | 5 | $95 |
| E.r. Squibb & Sons, L.L.C. | 5 | $85 |
| Beone Medicines USA, Inc. | 4 | $73 |
| Merck | 3 | $69 |
| Sanofi | 2 | $48 |
| Regeneron Healthcare Solutions, Inc. | 2 | $46 |
| Stemline Therapeutics Inc. | 2 | $43 |
| Bayer | 2 | $38 |
| Sobi, Inc | 2 | $37 |
| Gilead | 2 | $36 |
| Amgen | 1 | $30 |
| Array Biopharma Inc | 2 | $30 |
| Astellas Pharma US Inc | 1 | $28 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $26 |
| AVEO Pharmaceuticals, Inc. | 1 | $23 |
| Ipsen Biopharmaceuticals, Inc | 1 | $21 |
| Syndax Pharmaceuticals, Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$127,853 in reported general payments places this provider in the 90th percentile of 183 hematology & oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 314 | $4,563,245 |
| RevlimidLenalidomide | 156 | $2,995,681 |
| PomalystPomalidomide | 104 | $2,370,007 |
| ImbruvicaIbrutinib | 27 | $394,434 |
| InrebicFedratinib Dihydrochloride | 13 | $321,339 |
| NinlaroIxazomib Citrate | 22 | $280,905 |
| BrukinsaZanubrutinib | 21 | $267,779 |
| ScemblixAsciminib Hydrochloride | 12 | $243,419 |
| JakafiRuxolitinib Phosphate | 15 | $241,811 |
| VenclextaVenetoclax | 17 | $238,912 |
| CalquenceAcalabrutinib Maleate | 11 | $169,441 |
| OnuregAzacitidine | 11 | $144,027 |
| EliquisApixaban | 48 | $34,654 |
| OxycontinOxycodone Hcl | 21 | $19,378 |
| XareltoRivaroxaban | 14 | $14,370 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid, Inrebic | $95 | $3,317,020169 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Onureg | $85 | $2,514,033115 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $26 | $394,43427 claims |
| Beigene USA, Inc.Brukinsa | $704 | $267,77921 claims |
| NovartisScemblix | $326 | $243,41912 claims |
| Incyte CorporationJakafi | $99 | $241,81115 claims |
| AbbVieVenclexta | $161 | $238,91217 claims |
| AstraZenecaCalquence | $27,826 | $169,44111 claims |
| PfizerEliquis | $2,663 | $34,65448 claims |
| Johnson & JohnsonXarelto | $77,936 | $14,37014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 183 hematology & oncology providers in Louisiana.
Other hematology & oncology in Baton Rouge
- Hana SafahBaton Rouge$2M
- Nakhle SabaBaton Rouge$842K
- Sanjay JunejaBaton Rouge$346K
- Greg BizetteBaton Rouge$32K
- Marshall StaggBaton Rouge$19K
- Christopher McCanlessBaton Rouge$18K
- Georgios ConstantinouBaton Rouge$15K
- Lauren JunejaBaton Rouge$14K
- Victor LinBaton Rouge$10K
- Pedro BarataNew Orleans$928K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.